| 摘要 |
Described is a method of screening for therapeutic agents for the prophylaxis and therapy of Alzheimer's disease (AD), wherein agents that (i) do not interfere with the biological activity of gamma-secretase, (ii) do not exhibit cytotoxicity, (iii) lead to reduced amounts of Abeta42 and (iv) are capable of binding to an APP-GxxxG motif thereby weakening or inhibiting dimerization of the APP transmembrane sequence are suitable for prophylaxis or treatment of AD.
|
